First Light Asset Management, LLC
EDINA, MN · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.69B2026 Q3Cash-like 0.2%Weight of Treasury-bill ETFs of a year or less (SGOV, BIL, SHV, USFR, TFLO…) in the book. A 13F shows no cash or money-market funds; this is the closest the filing comes. It is not the fund's actual cash level.
Positions32
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.64.1%
What Changed This Quarter?
Top Holdings
AXGN
Axogen
9.3%
NEO
Neogenomics
9.2%
SIBN
Si-Bone
8.6%
AMLX
Amylyx Pharmaceuticals
6.9%
PVLA
Palvella Therapeutics
6.0%
EWTX
Edgewise Therapeutics
6.0%
TWST
Twist Bioscience
4.9%
MASS
908 Devices
4.9%
New / Increased
5 new · 11 increased
VERANEW
Vera Therapeutics
3.8%
INSPNEW
Inspire Medical Systems
2.5%
BBNXNEW
Beta Bionics
1.2%
BSXNEW
Boston Scientific
0.6%
BILNEW
SPDR Bloomberg Barclays
0.2%
EWTX
Edgewise Therapeutics
6.0%
+126.7%
AXGN
Axogen
9.3%
+36.0%
AMLX
Amylyx Pharmaceuticals
6.9%
+31.9%
Reduced / Exited
16 reduced · 4 sold out
NEO
Neogenomics
9.2%
-31.1%
TWST
Twist Bioscience
4.9%
-40.9%
ELVN
Enliven Therapeutics
2.8%
-25.2%
ANAB
Anaptys Bio
1.0%
-43.6%
PCVX
Vaxcyte
0.5%
-58.6%
Apogee Therap…EXIT
Apogee Therapeutics
7.5%
CRNXGBPEXIT
Crinetics Pharmaceuticals
3.1%
OMCLEXIT
Omnicell
1.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.